Novel Targets of Chemotherapeutic Drugs that Trap Protein on DNA

DNA 上捕获蛋白质的化疗药物新靶点

基本信息

批准号：
8878499
负责人：
Nancy Maizels
金额：
$ 16.8万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-03-10 至 2017-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8878499
关键词：
Adverse effects Azacitidine Binding Proteins Biochemical Biological Breast Carcinoma Cell physiology Cells Clinic Clinical Clinical Trials Colorectal Cancer Complex DNA DNA Adducts DNA Modification Methylases DNA Topoisomerases Decitabine Dose Doxorubicin Drug Targeting Drug effect disorder Drug usage Effectiveness Etoposide Funding Future Genes Goals Lead Malignant Neoplasms Malignant neoplasm of cervix uteri Methods Mutate Mutation Nucleic Acids Pharmaceutical Preparations Poison Proteins Proteomics RNA RNA Binding Small Interfering RNA Solid Neoplasm Specificity Spliceosomes TOP1 gene TOP2A gene Testing Topoisomerase Validation adduct covalent bond drug mechanism drug sensitivity human DNA improved insight irinotecan mRNA Export new therapeutic target novel novel strategies public health relevance research study small molecule success tool tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): Some very potent chemotherapeutics used in the clinic function by stabilizing covalent protein-DNA adducts formed as obligatory intermediates in normal cellular function. Despite the demonstrated effectiveness of these drugs, there has been no effort to systematically identify all targets of drugs in this class. Our proposal describes a novel approach that combines stringent enrichment of covalent protein adducts upon drug treatment with unbiased proteomics to identify and discover drug targets. Using this approach, we have confirmed known targets of topotecan and etoposide, and we have identified novel targets of these drugs, thereby establishing the power of this approach as a discovery tool. We propose to apply this approach to identify the targets of six chemotherapeutic drugs that function by this mechanism: etoposide, doxorubicin, topotecan, decitabine (5-aza-dC), azacitidine (5-aza-C) and olaparib, and to validate these targets. Success in these experiments will identify new targets of drugs in current use, and establish a general approach for determining mechanisms of drug action to enable future identification of novel drug-target pairs.

描述（由申请人提供）：临床上使用的一些非常有效的化疗药物通过稳定作为正常细胞功能中必需中间体形成的共价蛋白质-DNA 加合物发挥作用，尽管这些药物已被证明有效，但尚未努力系统地识别所有靶点。我们的提案描述了一种新方法，该方法将药物治疗时的共价蛋白加合物的严格富集与公正的蛋白质组学相结合，以识别和发现药物靶标，我们已经证实。拓扑替康和依托泊苷的已知靶点，并且我们已经确定了这些药物的新靶点，从而确立了这种方法作为发现工具的力量，我们建议应用这种方法来确定通过这种机制发挥作用的六种化疗药物的靶点：依托泊苷。、阿霉素、托泊替康、地西他滨 (5-aza-dC)、阿扎胞苷 (5-aza-C) 和奥拉帕尼，并验证这些实验的成功将确定这些目标。目前使用的药物的新靶点，并建立确定药物作用机制的通用方法，以便将来能够识别新的药物靶点对。